Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)
NCT00214110Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tamoxifen in amyotrophic lateral sclerosis (ALS), sponsored by University of Wisconsin–Madison. Primary endpoint: Mean percent predicted arm strength stability at 24 months. Started Jan 2001; status: completed.
02
Drugs
tamoxifen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00214110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00214110.